Cancer-Associated Exosomal CBFB Facilitates the Aggressive Phenotype, Evasion of Oxidative Stress, and Preferential Predisposition to Bone Prometastatic Factor of Breast Cancer Progression

Figure 1

CBFB expression is upregulated in triple-negative breast cancer (TNBC) cells and correlates with poor prognosis. (a) The Cancer Genome Atlas (TCGA) cohort exhibits abnormal CBFB expression in breast cancer and triple-negative breast cancer tissues. Increased CBFB expression is associated with metastasis and poor prognosis in patients with breast cancer. (b) A Kaplan–Meier metastasis-free survival curve derived from GSE25066 breast cancer cohort () reveals a shorter metastasis-free survival time for patients with a higher level of CBFB and NAE1. (c) Comparative qPCR analysis of CBFB expression between immortalized human mammary fibroblast (HMF3A), normal-like breast (MCF10A), low-metastatic-potential (MCF12A and T74D), and metastatic breast cancer (MDA-MB-436 and MDA-MB-157) cell lines. We observed the CBFB mRNA expression level in HMF3A, MCF10A, MCF12A, and T74D did not differ significantly. CBFB mRNA level was significantly higher in both metastatic cell lines, MDA-MB-436 and MDA-MB-157, than in normal-like breast cell line (MCF10A) and low-metastatic-potential MCF12A and T47D counterparts. (d) Different CBFB mRNA expression between nonmetastasis versus bone metastasis samples. (e–g) The expression of CBFB and oxidative stress–related targets NFATC3, NAE1, and TMEM170A. Patients with bone metastasis exhibited the highest CBFB among all samples (graph generated from http://gepia2.cancer-pku.cn/#survival). Each group consists of 10 samples. NS: not significant; , .

(a)

(b)

(c)

(d)

(e)

(f)

(g)